288 related articles for article (PubMed ID: 15890842)
1. Orphanin FQ/nociceptin potentiates [D-Ala2,N-Me-Phe4,Gly5-ol]-enkephalin-Induced mu-opioid receptor phosphorylation.
Ozsoy HZ; Thakker DR; Standifer KM
Mol Pharmacol; 2005 Aug; 68(2):447-56. PubMed ID: 15890842
[TBL] [Abstract][Full Text] [Related]
2. Mu-opioid-induced desensitization of opioid receptor-like 1 and mu-opioid receptors: differential intracellular signaling determines receptor sensitivity.
Mandyam CD; Thakker DR; Standifer KM
J Pharmacol Exp Ther; 2003 Sep; 306(3):965-72. PubMed ID: 12750434
[TBL] [Abstract][Full Text] [Related]
3. Orphanin FQ/nociceptin-mediated desensitization of opioid receptor-like 1 receptor and mu opioid receptors involves protein kinase C: a molecular mechanism for heterologous cross-talk.
Mandyam CD; Thakker DR; Christensen JL; Standifer KM
J Pharmacol Exp Ther; 2002 Aug; 302(2):502-9. PubMed ID: 12130708
[TBL] [Abstract][Full Text] [Related]
4. Nociceptin (ORL-1) and mu-opioid receptors mediate mitogen-activated protein kinase activation in CHO cells through a Gi-coupled signaling pathway: evidence for distinct mechanisms of agonist-mediated desensitization.
Hawes BE; Fried S; Yao X; Weig B; Graziano MP
J Neurochem; 1998 Sep; 71(3):1024-33. PubMed ID: 9721727
[TBL] [Abstract][Full Text] [Related]
5. Functional antagonism of mu-, delta- and kappa-opioid antinociception by orphanin FQ.
Mogil JS; Grisel JE; Zhangs G; Belknap JK; Grandy DK
Neurosci Lett; 1996 Aug; 214(2-3):131-4. PubMed ID: 8878101
[TBL] [Abstract][Full Text] [Related]
6. [Nphe1,Arg14,Lys15]N/OFQ-NH2 is a competitive antagonist of NOP receptors in the periaqueductal gray.
Chiou LC; Liao YY; Guerrini R; Calo' G
Eur J Pharmacol; 2005 May; 515(1-3):47-53. PubMed ID: 15896734
[TBL] [Abstract][Full Text] [Related]
7. A cluster of Ser/Thr residues at the C-terminus of mu-opioid receptor is required for G protein-coupled receptor kinase 2-mediated desensitization.
Wang HL
Neuropharmacology; 2000 Jan; 39(3):353-63. PubMed ID: 10698001
[TBL] [Abstract][Full Text] [Related]
8. Agonist-selective mechanisms of mu-opioid receptor desensitization in human embryonic kidney 293 cells.
Johnson EA; Oldfield S; Braksator E; Gonzalez-Cuello A; Couch D; Hall KJ; Mundell SJ; Bailey CP; Kelly E; Henderson G
Mol Pharmacol; 2006 Aug; 70(2):676-85. PubMed ID: 16682505
[TBL] [Abstract][Full Text] [Related]
9. Induction of G protein-coupled receptor kinases 2 and 3 contributes to the cross-talk between mu and ORL1 receptors following prolonged agonist exposure.
Thakker DR; Standifer KM
Neuropharmacology; 2002 Nov; 43(6):979-90. PubMed ID: 12423667
[TBL] [Abstract][Full Text] [Related]
10. Differential antagonism by naloxone benzoylhydrazone of the activation of inward rectifying K+ channels by nociceptin and a mu-opioid in rat periaqueductal grey slices.
Chiou LC
Naunyn Schmiedebergs Arch Pharmacol; 2001 Jun; 363(6):583-9. PubMed ID: 11414652
[TBL] [Abstract][Full Text] [Related]
11. Blockade of the nociceptin/orphanin FQ/NOP receptor system in the rat ventrolateral periaqueductal gray potentiates DAMGO analgesia.
Scoto GM; Aricò G; Ronsisvalle S; Parenti C
Peptides; 2007 Jul; 28(7):1441-6. PubMed ID: 17628212
[TBL] [Abstract][Full Text] [Related]
12. Role of protein kinase C (PKC) in agonist-induced mu-opioid receptor down-regulation: II. Activation and involvement of the alpha, epsilon, and zeta isoforms of PKC.
Kramer HK; Simon EJ
J Neurochem; 1999 Feb; 72(2):594-604. PubMed ID: 9930731
[TBL] [Abstract][Full Text] [Related]
13. [Nphe(1)]N/OFQ-(1-13)-NH(2) is a competitive and selective antagonist at nociceptin/orphanin FQ receptors mediating K(+) channel activation in rat periaqueductal gray slices.
Chiou LC; Fan SH; Guerrini R; Caló G
Neuropharmacology; 2002 Feb; 42(2):246-52. PubMed ID: 11804621
[TBL] [Abstract][Full Text] [Related]
14. Pharmacological characterization of inhibitory effects of postsynaptic opioid and cannabinoid receptors on calcium currents in neonatal rat nucleus tractus solitarius.
Endoh T
Br J Pharmacol; 2006 Feb; 147(4):391-401. PubMed ID: 16402042
[TBL] [Abstract][Full Text] [Related]
15. The absence of a direct correlation between the loss of [D-Ala2, MePhe4,Gly5-ol]Enkephalin inhibition of adenylyl cyclase activity and agonist-induced mu-opioid receptor phosphorylation.
El Kouhen R; Kouhen OM; Law PY; Loh HH
J Biol Chem; 1999 Apr; 274(14):9207-15. PubMed ID: 10092593
[TBL] [Abstract][Full Text] [Related]
16. The functional antiopioid action of the ventrolateral periaqueductal gray nociceptin/orphanin FQ and nociceptin receptor system underlies DAMGO analgesic tolerance.
Parenti C; Scoto GM
Pharmacology; 2010; 86(3):138-44. PubMed ID: 20689345
[TBL] [Abstract][Full Text] [Related]
17. Comparison of [Dmt1]DALDA and DAMGO in binding and G protein activation at mu, delta, and kappa opioid receptors.
Zhao GM; Qian X; Schiller PW; Szeto HH
J Pharmacol Exp Ther; 2003 Dec; 307(3):947-54. PubMed ID: 14534366
[TBL] [Abstract][Full Text] [Related]
18. G protein-coupled receptor kinase 2 mediates mu-opioid receptor desensitization in GABAergic neurons of the nucleus raphe magnus.
Li AH; Wang HL
J Neurochem; 2001 Apr; 77(2):435-44. PubMed ID: 11299306
[TBL] [Abstract][Full Text] [Related]
19. 1-Benzyl-N-[3-[spiroisobenzofuran-1(3H),4'-piperidin-1-yl]propyl]pyrrolidine-2-carboxamide (Compound 24) antagonizes NOP receptor-mediated potassium channel activation in rat periaqueductal gray slices.
Liao YY; Trapella C; Chiou LC
Eur J Pharmacol; 2009 Mar; 606(1-3):84-9. PubMed ID: 19374842
[TBL] [Abstract][Full Text] [Related]
20. Effect of agmatine on DAMGO-induced mu-opioid receptor down-regulation and internalization via activation of IRAS, a candidate for imidazoline I(1) receptor.
Gao Y; Li F; Wu N; Su RB; Liu Y; Lu XQ; Liu Y; Li J
Eur J Pharmacol; 2008 Dec; 599(1-3):18-23. PubMed ID: 18845140
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
